Literature DB >> 29183888

Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes.

Anuhya Kommalapati1, Sri Harsha Tella1, Martin Durkin2, Ronald S Go3, Gaurav Goyal3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29183888      PMCID： PMC5757688          DOI： 10.1182/blood-2017-10-812495

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Monocyte/Macrophage-specific marker CD163+ histiocytic sarcoma: case report with clinical, morphologic, immunohistochemical, and molecular genetic studies.

Authors:  Makoto Mikami; Yoshito Sadahira; Yoshimasa Suetsugu; Hideho Wada; Takashi Sugihara
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

2.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

3.  High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas.

Authors:  Wei Chen; Sean K Lau; Dean Fong; Jun Wang; Endi Wang; Daniel A Arber; Lawrence M Weiss; Qin Huang
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

4.  Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.

Authors:  Jason L Hornick; Elaine S Jaffe; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

5.  Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone.

Authors:  Andrew L Feldman; Daniel A Arber; Stefania Pittaluga; Antonio Martinez; Jerome S Burke; Mark Raffeld; Mireia Camos; Roger Warnke; Elaine S Jaffe
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

6.  Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry.

Authors:  Chikamasa Yoshida; Makoto Takeuchi
Journal:  Intern Med       Date:  2008-02-01       Impact factor: 1.271

7.  Leukemic Transdifferentiation of Follicular Lymphoma Into an Acute Histiocytic Leukemia in a 52-Year-Old Caucasian Woman.

Authors:  Bryan Steussy; Jacqueline Lekostaj; Qining Qian; Nancy Rosenthal; Carol J Holman; Sergei Syrbu; Benjamin Darbro; Aaron Bossler; Nitin J Karandikar
Journal:  Lab Med       Date:  2016-05
  7 in total
  24 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 2.  Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.

Authors:  Gaurav Goyal; Denise Lau; Alison M Nagle; Robert Vassallo; Karen L Rech; Jay H Ryu; Caroline J Davidge-Pitts; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Mithun V Shah; Minetta C Liu; Ronald S Go
Journal:  Blood       Date:  2019-01-29       Impact factor: 22.113

3.  Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.

Authors:  Marilia Takada; Lauren A Smyth; Jeremy Ml Hix; Sarah M Corner; Matti Kiupel; Vilma Yuzbasiyan-Gurkan
Journal:  Comp Med       Date:  2019-02-04       Impact factor: 0.982

4.  Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Authors:  Sophie Voruz; Filipe Martins; Anne Cairoli; Olaia Naveiras; Krisztian Homicsko; Edoardo Missiaglia; Laurence de Leval; Bettina Bisig; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

5.  Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Authors:  Jennifer A Lenz; Charles-Antoine Assenmacher; Victoria Costa; Katie Louka; Suzanne Rau; Nicholas S Keuler; Paul J Zhang; Robert G Maki; Amy C Durham; Enrico Radaelli; Matthew J Atherton
Journal:  Cancer Immunol Immunother       Date:  2021-08-20       Impact factor: 6.968

6.  Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.

Authors:  Osamu Imataki; Makiko Uemura; Haruyuki Fujita; Norimitsu Kadowaki
Journal:  Mol Clin Oncol       Date:  2022-07-15

7.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

8.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

9.  Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

Authors:  Mrinal M Gounder; David B Solit; William D Tap
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

10.  Case Report: Eighteen Month Relapse- Free Survival Following Radical Multidisciplinary Oncological Treatment in a 68-Year-Old Male Patient With Histiocytic Sarcoma.

Authors:  Stefan Wehrmann; Hagen Rudolph; Dominikus Ernst; Timo Siepmann; Dorothea Kaltofen; Mathias Hänel; Lutz Mirow
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.